🇺🇸 FDA
Pipeline program

A study to learn more about the safety and effects of a new blood-thinning medicine, given alone and together with another blood-thinner, in healthy adults

22806

Phase 1 other active

Quick answer

A study to learn more about the safety and effects of a new blood-thinning medicine, given alone and together with another blood-thinner, in healthy adults for atrial fibrillation, transient ischemic attack (TIA), ischemic stroke is a Phase 1 program (other) at Bayer AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bayer AG
Indication
atrial fibrillation, transient ischemic attack (TIA), ischemic stroke
Phase
Phase 1
Modality
other
Status
active

Clinical trials